Summary:
A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluationgthe efficacy and safety of bimekizumab in subjects with active Nonradiographic Axial Spondyloarthritis.
Qualified Participants Must:
• Subject is male or female at least 18 years of age
• Inflamatory back pain for at least 3 months prior to screening visit
• Age at symptoms onset prior to age 45
• Inadequate response to NSAID therapy or intolerance to administration of at least 1 NSAID
• Subjects must have active disease as defined by both of the following visits screening and baseline.
Qualified Participants May Receive:
Free study medication if qualify and enrolled into the study. Free doctor visits along with blood results. Once you are qualified and enrolled into study you will receive $40.00 per visit completed.